Current and future pharmacological interventions for the acute treatment of ischaemic stroke

Current Anaesthesia and Critical Care

Volumn 16, Issue 2, 2005, Pages 99-109

  Rahman, Rosanna M A ^a   Nair, Shiva M ^a   Appleton, Ian ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Acute therapy; Autoimmunity; Clinical trials; Inflammation; Ischaemic stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANCROD; DESMOTEPLASE; EBSELEN; FIBRINOLYTIC AGENT; FIBRINOPEPTIDE A; GANGLIOTETRAOSYLCERAMIDE; HEPARIN; INTERLEUKIN 6; LUBELUZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; NORPHENAZONE; PIOGLITAZONE; PLACEBO; PLASMINOGEN; PROSTAGLANDIN SYNTHASE; PROUROKINASE; STREPTOKINASE; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; WARFARIN; [[3,4 DIHYDRO 7 MORPHOLINO 2,3 DIOXO 6 (TRIFLUOROMETHYL) 1(2H) QUINOXALINYL]METHYL]PHOSPHONIC ACID;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AUTOIMMUNITY; BRAIN HEMORRHAGE; BRAIN RADIOGRAPHY; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FIBRINOLYSIS; FOLLOW UP; GENETIC PREDISPOSITION; GENETIC RISK; HEALTH EDUCATION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MORTALITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

EID: 24344443693     PISSN: 09537112     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cacc.2005.04.003     Document Type: Article

References (81)

1. R. Bonita Stroke prevention: A global perspective In: J.W. Norris V. Hachinski editors. Stroke prevention 2001 Oxford University Press New York 259-274
2. F.C. Barone G.Z. Feuerstein Inflammatory mediators and stroke: New opportunities for novel therapeutics J Cereb Blood Flow Metab 19 8 1999 819-834
3. Kasner SE, Gorelick PB, editors. Prevention and treatment of ischemic stroke. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, editors. Stroke: pathophysiology, diagnosis, and management, 3rd ed. New York: Churchill Livingstone; 1998. p. 3-28
4. Stroke Therapy Academic Industry Roundtable II (STAIR-II) Recommendations for clinical trial evaluation of acute stroke therapies Stroke 32 7 2001 1598-1606
5. Recommendations for standards regarding preclinical neuroprotective and restorative drug development Stroke 30 12 1999 2752-2758
6. M. Fisher Stroke Therapy Academic Industry Roundtable Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3 Stroke 34 6 2003 1539-1546
7. A.R. Green Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective Clin Exp Pharmacol Physiol 29 11 2002 1030-1034
8. J. Grotta Neuroprotection is unlikely to be effective in humans using current trial designs Stroke 33 2001 306-307
9. A.J. Hunter A.R. Green A.J. Cross Animal models of acute ischaemic stroke: Can they predict clinically successful neuroprotective drugs? Trends Pharmacol Sci 16 4 1995 123-128
10. A.R. Green T. Odergren T. Ashwood Animal models of stroke: Do they have value for discovering neuroprotective agents? Trends Pharmacol Sci 24 8 2003 402-408
11. M.J. Alberts C. Bertels D.V. Dawson An analysis of time of presentation after stroke JAMA 263 1 1990 65-68
12. K.W. Muir K.R. Lees I. Ford S. Davis Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): Randomised controlled trial Lancet 363 9407 2004 439-445
13. G.L. Lenzi F. Grigoletto M. Gent R.S. Roberts M.D. Walker J.D. Easton et al. Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the Early Stroke Trial Stroke 25 8 1994 1552-1558
14. Tissue plasminogen activator for acute ischemic stroke The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group N Engl J Med 333 24 1995 1581-1587
15. M.D. Hill V. Hachinski Stroke treatment: Time is brain Lancet 352 Suppl. 3 1998 SIII10-SIII14
16. D.G. Sherman R.P. Atkinson T. Chippendale K.A. Levin K. Ng N. Futrell C.Y. Hsu et al. Intravenous ancrod for treatment of acute ischemic stroke: ThA STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial JAMA 283 18 2000 2395-2403
17. L. Turski A. Huth M. Sheardown F. McDonald R. Neuhaus H.H. Schneider et al. ZK200775: A phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma Proc Natl Acad Sci USA 95 18 1998 10960-10965
18. J.W. Elting G.A. Sulter M. Kaste K.R. Lees H.C. Diener M. Hommel et al. AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels Stroke 33 12 2002 2813-2818
19. K.T. Tan G.Y. Lip A.D. Blann Post-stroke inflammatory response: Effects of stroke evolution and outcome Curr Atheroscler Rep 5 4 2003 245-251
20. A.N. Clarkson R. Rahman I. Appleton Inflammation and autoimmunity as a central theme in neurodegenerative disorders: Fact or fiction? Curr Opin Investig Drugs 5 7 2004 706-713
21. U. Dirnagl C. Iadecola M.A. Moskowitz Pathobiology of ischaemic stroke: an integrated view Trends Neurosci 22 9 1999 391-397
22. H.J. Jeong S.H. Hong H.J. Park D.Y. Kweon S.W. Lee J.D. Lee et al. Yangkyuk-Sanhwa-Tang induces changes in serum cytokines and improves outcome in focal stroke patients Vascul Pharmacol 39 1-2 2002 63-68
23. H. Suzuki K. Abe S.J. Tojo H. Kitagawa K. Kimura M. Mizugaki et al. Reduction of ischemic brain injury by anti-P-selectin monoclonal antibody after permanent middle cerebral artery occlusion in rat Neurol Res 21 3 1999 269-276
24. N. Vila J. Castillo A. Davalos A. Esteve A.M. Planas A. Chamorro Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke Stroke 34 3 2003 671-675
25. N. Vila J. Castillo A. Davalos A. Chamorro Proinflammatory cytokines and early neurological worsening in ischemic stroke Stroke 31 10 2000 2325-2329
26. M. Di Napoli Early inflammatory response in ischemic stroke Thromb Res 103 3 2001 261-264
27. R. Kazmierski P. Guzik W. Ambrosius A. Ciesielska J. Moskal W. Kozubski Predictive value of white blood cell count on admission for in-hospital mortality in acute stroke patients Clin Neurol Neurosurg 107 1 2004 38-43
28. S. Jander M. Schroeter G. Stoll Role of NMDA receptor signaling in the regulation of inflammatory gene expression after focal brain ischemia J Neuroimmunol 109 2 2000 181-187
29. Clarkson AN, Liu H, Rahman R, Jackson D, Appleton I, Kerr D. Clomethiazole: Mechanisms underlying lasting neuroprotection after hypoxia-ischemia. FASEB J, 2005; Epub; April 4, 2005.
30. C. Iadecola M. Alexander Cerebral ischemia and inflammation Curr Opin Neurol 14 1 2001 89-94
31. H.C. Emsley C.J. Smith C.M. Gavin R.F. Georgiou A. Vail E.M. Barberan et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: Relationships with infection and atherosclerosis J Neuroimmunol 139 1-2 2003 93-101
32. G. del Zoppo I. Ginis J.M. Hallenbeck C. Iadecola X. Wang G.Z. Feuerstein Inflammation and stroke: Putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia Brain Pathol 10 1 2000 95-112
33. G.H. Danton W.D. Dietrich Inflammatory mechanisms after ischemia and stroke J Neuropathol Exp Neurol 62 2 2003 127-136
34. K.J. Becker Targeting the central nervous system inflammatory response in ischemic stroke Curr Opin Neurol 14 3 2001 349-353
35. K. Becker D. Kindrick J. Relton J. Harlan R. Winn Antibody to the alpha4 integrin decreases infarct size in transient focal cerebral ischemia in rats Stroke 32 1 2001 206-211
36. R. Meller S.L. Stevens M. Minami J.A. Cameron S. King H. Rosenzweig et al. Neuroprotection by osteopontin in stroke J Cereb Blood Flow Metab 25 2 2005 217-225
37. L. Sironi E. Gianazza P. Gelosa U. Guerrini E. Nobili A. Gianella et al. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects Arterioscler Thromb Vasc Biol 25 3 2005 598-603
38. S. Sundararajan J.L. Gamboa N.A. Victor E.W. Wanderi W.D. Lust G.E. Landreth Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia Neuroscience 130 3 2005 685-696
39. S.L. Liao T.K. Kao W.Y. Chen Y.S. Lin S.Y. Chen S.L. Raung et al. Tetramethylpyrazine reduces ischemic brain injury in rats Neurosci Lett 372 1-2 2004 40-45
40. T. Watanabe Y. Okuda N. Nonoguchi M.Z. Zhao Y. Kajimoto D. Furutama et al. Postischemic intraventricular administration of FGF-2 expressing adenoviral vectors improves neurologic outcome and reduces infarct volume after transient focal cerebral ischemia in rats J Cereb Blood Flow Metab 24 11 2004 1205-1213
41. M. Khan B. Sekhon S. Giri M. Jatana A.G. Gilg K. Ayasolla et al. S-Nitrosoglutathione reduces inflammation and protects brain against focal cerebral ischemia in a rat model of experimental stroke J Cereb Blood Flow Metab 25 2 2005 177-192
42. H.S. Han M.A. Yenari Cellular targets of brain inflammation in stroke Curr Opin Investig Drugs 4 5 2003 522-529
43. D. Xue Z.G. Huang K.E. Smith A.M. Buchan Immediate or delayed mild hypothermia prevents focal cerebral infarction Brain Res 587 1 1992 66-72
44. J. Reith H.S. Jorgensen P.M. Pedersen H. Nakayama H.O. Raaschou L.L. Jeppesen et al. Body temperature in acute stroke: Relation to stroke severity, infarct size, mortality, and outcome Lancet 347 8999 1996 422-425
45. M. Chopp Y. Li M.O. Dereski S.R. Levine Y. Yoshida J.H. Garcia Hypothermia reduces 72-kDa heat-shock protein induction in rat brain after transient forebrain ischemia Stroke 23 1 1992 104-107
46. M.D. Ginsberg R. Busto Combating hyperthermia in acute stroke: A significant clinical concern Stroke 29 2 1998 529-534
47. D.W. Krieger M.A. De Georgia A. Abou-Chebl J.C. Andrefsky C.A. Sila I.L. Katzan et al. Cooling for acute ischemic brain damage (cool aid): An open pilot study of induced hypothermia in acute ischemic stroke Stroke 32 8 2001 1847-1854
48. A.I. Qureshi Nonsteroidal anti-inflammatory drugs and the risk of intracerebral haemorrhage Stroke 34 2003 385-386
49. S. Bak M. Andersen I. Tsiropoulos L.A. Garcia Rodriguez J. Hallas K. Christensen et al. Risk of stroke associated with nonsteroidal anti-inflammatory drugs: A nested case-control study Stroke 34 2 2003 379-386
50. G.A. FitzGerald Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: Clinical considerations Am J Cardiol 89 6A 2002 26D-32D
51. D.W. Clark D. Layton S.A. Shakir Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology Drug Saf 27 7 2004 427-456
52. Edaravone Acute Infarction Study Group Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters Cerebrovasc Dis 15 3 2003 222-229
53. T. Yamaguchi K. Sano K. Takakura I. Saito Y. Shinohara T. Asano H. Yasuhara Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial Ebselen Study Group. Stroke 29 1 1998 12-17
54. M. Schroeter S. Jander O.W. Witte G. Stoll Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion J Neuroimmunol 55 2 1994 195-203
55. R.A. Elkarim M. Mustafa P. Kivisakk H. Link M. Bakhiet Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke Eur J Clin Invest 28 4 1998 295-299
56. M.A. van Boekel W.J. van Venrooij Modifications of arginines and their role in autoimmunity Autoimmun Rev 2 2 2003 57-62
57. P.J. Lindsberg A.J. Grau Inflammation and infections as risk factors for ischemic stroke Stroke 34 10 2003 2518-2532
58. T.J. DeGraba Immunogenetic susceptibility of atherosclerotic stroke: implications on current and future treatment of vascular inflammation Stroke 35 11 Suppl. 1 2004 2712-2719
59. R.Y. Zee N.R. Cook S. Cheng R. Reynolds H.A. Erlich K. Lindpaintner et al. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: A population-based, prospective genetic analysis Hum Mol Genet 13 4 2004 389-396
60. Roitt I, Brostoff J, Male D, editors. Immunology, 5th ed. London: Mosby International Ltd.; 1998. p. 171-4, 196-7.
61. C.A. Janeway P. Travers M. Walport M.J. Shlomchik editors. Immunobiology 5: The immune system in health and disease 2001 Garland Publishing New York 410-411
62. H.L. Weiner D.J. Selkoe Inflammation and therapeutic vaccination in CNS diseases Nature 420 6917 2002 879-884
63. Ancrod for the treatment of acute ischemic brain infarction The Ancrod Stroke Study Investigators Stroke 25 9 1994 1755-1759
64. J. Grotta Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group Stroke 28 12 1997 2338-2346
65. A. Furlan R. Higashida L. Wechsler M. Gent H. Rowley C. Kase et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism JAMA 282 21 1999 2003-2011
66. W. Hacke G. Albers Y. Al-Rawi J. Bogousslavsky A. Davalos M. Eliasziw et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase Stroke 36 1 2005 66-73
67. Y.P. Gobin S. Starkman G.R. Duckwiler T. Grobelny C.S. Kidwell R. Jahan et al. MERCI 1: A phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia Stroke 35 12 2004 2848-2854
68. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke CAST (Chinese Acute Stroke Trial) Collaborative Group Lancet 349 9066 1997 1641-1649
69. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke International Stroke Trial Collaborative Group Lancet 349 9065 1997 1569-1581
70. W.S. Aronow C. Ahn I. Kronzon H. Gutstein Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction Am J Cardiol 85 8 2000 1033-1035
71. G.W. Albers V.E. Bates W.M. Clark R. Bell P. Verro S.A. Hamilton Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study JAMA 283 9 2000 1145-1150
72. G.A. Donnan S.M. Davis B.R. Chambers P.C. Gates G.J. Hankey J.J. McNeil et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group JAMA 276 12 1996 961-966
73. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke Multicentre Acute Stroke Trial - Italy (MAST-I) Group Lancet 346 8989 1995 1509-1514
74. Thrombolytic therapy with streptokinase in acute ischemic stroke The Multicenter Acute Stroke Trial-Europe Study Group N Engl J Med 335 3 1996 145-150
75. W. Hacke M. Kaste C. Fieschi R. von Kummer A. Davalos D. Meier et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Second European-Australasian Acute Stroke Study Investigators Lancet 352 9136 1998 1245-1251
76. P. Jerrard-Dunne G. Cloud A. Hassan H.S. Markus Evaluating the genetic component of ischemic stroke subtypes: A family history study Stroke 34 6 2003 1364-1369
77. N.G. Wahlgren K.W. Ranasinha T. Rosolacci C.L. Franke P.M. van Erven T. Ashwood et al. Clomethiazole acute stroke study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients Stroke 30 1 1999 21-28
78. J. Ourednik V. Ourednik W.P. Lynch M. Schachner E.Y. Snyder Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons Nat Biotechnol 20 11 2002 1103-1110
79. J.D. Rothstein E.Y. Snyder Reality and immortality - neural stem cells for therapies Nat Biotechnol 22 3 2004 283-285
80. E.Y. Snyder K.I. Park Limitations in brain repair Nat Med 8 9 2002 928-930
81. J.L. Wilterdink B. Bendixen H.P. Adams Jr R.F. Woolson W.R. Clarke M.D. Hansen Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST) Stroke 32 12 2001 2836-2840